Literature DB >> 30296503

Renal Hilar Lesions: Biological Implications for Complex Partial Nephrectomy.

Andres F Correa1, Hilary Yankey2, Tianyu Li3, Shreyas S Joshi4, Alexander Kutikov4, David Y Chen4, Rosalia Viterbo4, Richard E Greenberg4, Marc C Smaldone4, Robert G Uzzo4.   

Abstract

OBJECTIVE: To perform a comprehensive histopathologic review of sporadic resected solitary cT1 renal masses comparing those with and without radiographic involvement of the hilum.
MATERIALS AND METHODS: A prospectively maintained database was queried for all cT1 renal masses undergoing resection classified per the R.E.N.A.L. nephrometry score. Hilar masses were defined as tumors that abut the main renal artery or vein on cross-sectional imaging. Demographic, treatment, renal mass, and histopathologic characteristics were compared between hilar and nonhilar renal masses. Multivariate regression model analyses were performed to assess factors associated with renal mass upstaging and disease recurrence.
RESULTS: A total of 1324 stage 1 renal masses met criteria for analysis of which 226 (17.1%) were defined as hilar. Hilar masses were larger, scored with higher complexity, and more likely to undergo a radical nephrectomy. On histopathologic analysis, we found no difference between hilar and nonhilar masses regarding the incidence of malignancy, presence of high nuclear grade, or risk of upstaging. On multivariate analysis, a tumor's hilar location was not associated with upstaging or disease recurrence.
CONCLUSION: We present a comprehensive histopathologic review of a large cohort of cT1 hilar lesions noting no difference in the risk of malignancy, high nuclear grade, upstaging, or recurrence when compared to nonhilar lesions. Together, these data suggest that there is no compelling cancer-specific rationale to perform a radical nephrectomy when managing renal hilar tumors.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30296503     DOI: 10.1016/j.urology.2018.08.044

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  Role of minimally invasive partial nephrectomy in the management of renal mass.

Authors:  Randall A Lee; David Strauss; Alexander Kutikov
Journal:  Transl Androl Urol       Date:  2020-12

Review 2.  The future of "Retro" robotic partial nephrectomy.

Authors:  David M Strauss; Randall Lee; Fenizia Maffucci; Daniel Abbott; Selma Masic; Alexander Kutikov
Journal:  Transl Androl Urol       Date:  2021-05

3.  Trifecta and pentafecta outcomes following robot-assisted partial nephrectomy for hilar versus nonhilar tumors: A propensity-matched analysis.

Authors:  Shantanu Tyagi; Gopal Sharma; Girdhar S Bora; Ravimohan S Mavuduru; Aditya Prakash Sharma; Sudheer Kumar Devana; Ujjwal Gorsi; Nandita Kakkar; Shrawan K Singh
Journal:  Indian J Urol       Date:  2021-10-01

4.  Machine Learning-Based MRI LAVA Dynamic Enhanced Scanning for the Diagnosis of Hilar Lesions.

Authors:  Haijin Wang; Song Wang; Lihua Zhou
Journal:  Comput Math Methods Med       Date:  2022-02-24       Impact factor: 2.238

5.  Functional and Oncological Outcomes of Renal Surgery for Hilar Tumors: Informing the Decisions in Risk-Adapted Management.

Authors:  Ricardo G Alvim; Amy L Tin; Lucas Nogueira; Nathan C Wong; Renato C Fonseca; Daniel D Sjoberg; A Ari Hakimi; Karim A Touijer; Paul Russo; Jonathan A Coleman
Journal:  Urology       Date:  2021-07-29       Impact factor: 2.649

6.  Outcomes and predictors of benign histology in patients undergoing robotic partial or radical nephrectomy for renal masses: a multicenter study.

Authors:  Naveen Nandanan; Alessandro Veccia; Alessandro Antonelli; Ithaar Derweesh; Alexandre Mottrie; Andrea Minervini; Monish Aron; Giuseppe Simone; Umberto Capitanio; Claudio Simeone; Daniel Eun; Sisto Perdonà; James Porter; Chandru Sundaram; Chao Zhang; Robert Uzzo; Ben Challacombe; Lance J Hampton; Jihad Kaouk; Francesco Porpiglia; Riccardo Autorino
Journal:  Cent European J Urol       Date:  2020-03-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.